- Home
- VIRT vs HCM Comparison
VIRT vs HCM Comparison
Compare VIRT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIRT | HCM |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | VIRT | HCM |
|---|---|---|
| Price | $35.46 | $14.13 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 7 | 1 |
| Target Price | ★ $41.43 | $13.75 |
| AVG Volume (30 Days) | ★ 731.5K | 29.0K |
| Earning Date | 10-29-2025 | 08-07-2025 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 132.69 | N/A |
| EPS | ★ 4.62 | 0.53 |
| Revenue | ★ $2,694,104,000.00 | $602,197,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.54 |
| P/E Ratio | $7.68 | ★ $5.26 |
| Revenue Growth | ★ 41.05 | N/A |
| 52 Week Low | $31.89 | $11.51 |
| 52 Week High | $45.77 | $19.50 |
Technical Indicators
Market Signals| Indicator | VIRT | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 37.46 |
| Support Level | $34.16 | $14.11 |
| Resistance Level | $35.89 | $14.63 |
| Average True Range (ATR) | 0.86 | 0.27 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 77.99 | 21.69 |
Price Performance
Historical ComparisonAbout VIRT Virtu Financial Inc.
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.